Is DiaSorin profitable in 2026?

Yes. DiaSorin reported FY2025 net profit of EUR150 million (down 20% YoY) and adjusted net profit of EUR223 million on EUR1,195 million revenue as of December 31, 2025. Q1 2026 revenue then fell about 3% at constant FX, though FY2026 guidance of 5-6% growth was maintained as of May 8, 2026.

Could AI replace DiaSorin's diagnostics business?

No. DiaSorin's core immunoassay and molecular reagent chemistry requires FDA/CLIA per-assay clearances and an installed instrument base, which generative AI cannot replicate. The exposed layer is data analytics and interpretation software, where rival Thermo Fisher launched AI-driven Orbitrap analytics by July 2026.

DiaSorin is publicly traded on Borsa Italiana (ticker DIA) since July 2007. As of June 2026, IP Investimenti e Partecipazioni Srl holds about 44% of shares but 55-61% of voting rights via Italy's loyalty-voting mechanism, with Sarago entities linked to founders Rosa and Denegri holding a further roughly 8%.

Is Thermo Fisher DiaSorin's biggest competitor or its partner?

Both. Thermo Fisher's Fisher Scientific unit became DiaSorin's exclusive US hospital-channel distributor for LIAISON NES in January 2026, yet a July 10, 2026 report said DiaSorin rebuffed a takeover approach from Thermo Fisher, which also competes directly via Cepheid in near-patient molecular testing.

Will Thermo Fisher acquire DiaSorin?

Unconfirmed as of July 2026. A report dated around July 10, 2026 said DiaSorin had rejected a takeover approach from Thermo Fisher, its own LIAISON NES distribution partner since January 2026, but no official bid has been confirmed by either company.

How is DiaSorin's LIAISON NES point-of-care platform performing?

LIAISON NES received FDA clearance and CLIA waiver for a 4-Plex Respiratory panel in December 2025 and for Group A Streptococcus in June 2026. Management has set an internal target (vendor-claimed) of exceeding $150 million in US revenue from the platform by 2030.

Biotech tools companies · Italy

DiaSorin S.p.A.

diasorin.com ↗

Italian maker of diagnostic instruments and immunoassay/molecular test kits for hospitals and labs.

Defensible for now

Assessed 24 July 2026 · Evidence as of 24 July 2026

Real protection, with named pressure against it.

On the recordSince 24 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Confirmation or collapse of the reported Thermo Fisher takeover approach

The call

DiaSorin keeps its regulatory and installed-base position in specialty immunoassays intact while growth stalls and its biggest partner also looks like its biggest threat.

DiaSorin makes specialty diagnostic machines and tests that hospitals and labs use to detect diseases in blood samples. The company has built a durable business by getting FDA approval for each individual test and locking hospitals into its hardware, which makes it hard for competitors to steal customers, but that advantage will only last a few years. The real risk is that its main growth product competes directly with bigger, better-funded rivals like Thermo Fisher and Abbott, and Thermo Fisher is both DiaSorin's biggest sales partner in the U.S. hospital market and a company that reportedly approached to buy it in mid-2026, creating a potential conflict of interest that could reshape the entire situation within the next year.

Why

AI pressure: None apparent. No AI product yet threatens assay-based diagnostics directly, though rivals are adding AI analytics layers DiaSorin lacks. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific. Thermo Fisher is DiaSorin's US hospital-channel partner for LIAISON NES, a reported 2026 acquirer, and competes directly via Cepheid in molecular testing. Could a giant copy it? Probably.

What protects it. FDA/CLIA per-assay clearances plus an installed base of instruments locked to DiaSorin's own reagents.

What would change this call

Thermo Fisher confirms or drops its reported 2026 takeover approach to DiaSorin. Shows whether DiaSorin's distribution partner becomes owner or a fraying rival.
DiaSorin reports FY2026 revenue growth versus its 5-6% guided range at next earnings. Tests whether Q1 2026's -3% decline was temporary or a growth-story break.
News of Thermo Fisher ending or renewing LIAISON NES US hospital distribution exclusivity. Reveals whether DiaSorin's key growth product keeps US market access.

Key numbers

FY2025 revenue €1,195M, +1% at current FX (2025-12-31)
Q1 2026 revenue fell 3% at constant FX (2026-03-31)
FY2025 net profit €150M, down 20% YoY (2025-12-31)

Named risks

China volume-based procurement pricing erosion cited across FY2025 and Q1 2026 calls. Severity: medium
Dependence on Thermo Fisher, a reported would-be acquirer, as exclusive US LIAISON NES distributor since Jan 2026. Severity: high
Stock at 10-year lows since March 2026 with growth guidance cuts and analyst downgrades. Severity: medium
Late entry into point-of-care molecular testing dominated by Roche, Abbott, bioMerieux and Danaher. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	contesting	Exclusive US LIAISON NES distributor since Jan 2026 yet reportedly sought DiaSorin takeover by Jul 2026
Roche Diagnostics	gaining on	Larger cobas Liat point-of-care platform competes head-on with new LIAISON NES entry, 2026
Abbott Laboratories	gaining on	Entrenched ID NOW point-of-care system predates DiaSorin's LIAISON NES launch
bioMerieux	gaining on	BioFire already dominant in multiplex point-of-care molecular testing niche DiaSorin is entering
Danaher (Cepheid)	gaining on	GeneXpert entrenched in near-patient molecular testing ahead of DiaSorin's newer platforms

Questions people ask

Is DiaSorin profitable in 2026?: Yes. DiaSorin reported FY2025 net profit of EUR150 million (down 20% YoY) and adjusted net profit of EUR223 million on EUR1,195 million revenue as of December 31, 2025. Q1 2026 revenue then fell about 3% at constant FX, though FY2026 guidance of 5-6% growth was maintained as of May 8, 2026.
Could AI replace DiaSorin's diagnostics business?: No. DiaSorin's core immunoassay and molecular reagent chemistry requires FDA/CLIA per-assay clearances and an installed instrument base, which generative AI cannot replicate. The exposed layer is data analytics and interpretation software, where rival Thermo Fisher launched AI-driven Orbitrap analytics by July 2026.
Who owns DiaSorin?: DiaSorin is publicly traded on Borsa Italiana (ticker DIA) since July 2007. As of June 2026, IP Investimenti e Partecipazioni Srl holds about 44% of shares but 55-61% of voting rights via Italy's loyalty-voting mechanism, with Sarago entities linked to founders Rosa and Denegri holding a further roughly 8%.
Is Thermo Fisher DiaSorin's biggest competitor or its partner?: Both. Thermo Fisher's Fisher Scientific unit became DiaSorin's exclusive US hospital-channel distributor for LIAISON NES in January 2026, yet a July 10, 2026 report said DiaSorin rebuffed a takeover approach from Thermo Fisher, which also competes directly via Cepheid in near-patient molecular testing.
Will Thermo Fisher acquire DiaSorin?: Unconfirmed as of July 2026. A report dated around July 10, 2026 said DiaSorin had rejected a takeover approach from Thermo Fisher, its own LIAISON NES distribution partner since January 2026, but no official bid has been confirmed by either company.
How is DiaSorin's LIAISON NES point-of-care platform performing?: LIAISON NES received FDA clearance and CLIA waiver for a 4-Plex Respiratory panel in December 2025 and for Group A Streptococcus in June 2026. Management has set an internal target (vendor-claimed) of exceeding $150 million in US revenue from the platform by 2030.

Timeline

2026-07-10Report says DiaSorin rebuffed a takeover approach from Thermo Fisher Scientific
2026-06-22LIAISON NES Group A Streptococcus assay receives FDA clearance and CLIA waiver
2026-05-20LIAISON PLEX 24-pathogen Gastrointestinal Flex Assay cleared by FDA
2026-05-15Board approves 2026-2030 Business Plan targeting 6-8% revenue CAGR
2026-05-08Q1 2026 revenue falls ~3% at constant FX; FY2026 guidance maintained
2026-03-23Stock hits 10-year lows, down ~32% YoY, after FY2025 results disappoint
2026-03-20FY2025 results: revenue EUR1,195M (+1%), EBITDA margin 33%, net profit EUR150M
2026-01-01Exclusive US hospital-channel distribution deal signed with Fisher Scientific for LIAISON NES
2025-12-01LIAISON NES 4-Plex Respiratory panel gets FDA clearance and CLIA waiver
2024-03-01LIAISON PLEX Respiratory Panel receives FDA 510(k) clearance

Revision history

24 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Spectris plc Tecan Group Rigaku Corporation